Gilead shores up hope for NASH cocktail with a glimpse at positive proof-of-concept data
When Gilead conceded failure in its high-profile Phase III study for top late-stage NASH drug selonsertib, CSO John McHutchison pointed disappointed investors to a combination approach being tested in a mid-stage trial. Those data are not ready just yet, but today the big biotech unveiled some early numbers to bolster their case for a cocktail.
On display today at the International Liver Congress are topline results from a proof-of-concept study testing cilofexor (nonsteroidal farnesoid X receptor or FXR agonist) and firsocostat (acetyl-CoA carboxylase or ACC inhibitor). Out of 20 patients who were treated with the oral regimen once daily for 12 weeks, 74% experienced “a significant decline of at least 30 percent in hepatic fat” — a hallmark of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.